Algorithmic Tests
PROVIDERS/ONCOLOGY
The STAR Health Network algorithmic test platform leverages our molecular and clinical database, CAP/CLIA lab, and clinician network to develop tests that help inform the treatment of cancer patients.
LABORATORY DEVELOPED TESTS
AI-Driven HRD Tests
STAR Health Network HRD is a laboratory developed test to predict the probability of a patient’s cancer having a phenotype characterized by the inability to repair DNA breaks via the homologous recombination repair (HRR) pathway, known as homologous recombination deficiency (HRD). It is available as an additional test for patients who are tested with STAR Health Network xT.
For ovarian and breast cancer where DNA based methods of HRD detection are common or under investigation, STAR Health Network HRD provides a result based on DNA genome-wide loss of heterozygosity (GWLOH) or evidence of biallelic BRCA1 or BRCA2 loss. For patients with other cancers, STAR Health Network HRD provides an HRD score based on whole transcriptome RNA expression.
STAR Health Network HRD Advantages
No additional tissue required
HRD can be ordered as an add-on with any STAR Health Network xT test, without additional tissue samples.
A more complete patient view in one test
Gain additional insight into a patient’s tumor molecular phenotype on top of the genomic profiling results assessed by xT.
AI Drivent To Test
The STAR Health Network Tumor Origin (TO) test uses tumor RNA expression results to predict the patient’s most likely cancer type(s) from 68 possible cancer types. The STAR Health Network TO test was developed using a large internal database of clinical and annotated molecular tumor data.
The intended use of the TO test is for cancers of unknown primary and cases for which the available diagnostic information, such as imaging and immunohistochemistry results, do not provide a definitive diagnosis. When paired with xT, the TO results may provide insight into the patient’s diagnosis and tumor site of origin that may be used to inform patient care and clinical trial eligibility.
STAR Health Network TO Advantages
No additional tissue required
TO can be ordered as an add-on with any STAR Health Network xT test, without additional tissue samples.
Coverage of many cancer types
The test characterizes 68 possible cancer types to provide precise information for guiding treatment decisions.
DPYD Test
The DPYD gene encodes the enzyme dihydropyrimidine dehydrogenase (DPD), a key protein involved in 5-FU/Capecitabine metabolism.
The STAR Health Network DPYD test is designed to help physicians to better identify patients who may be at risk for toxicity and serious adverse effects from 5-FU/Capecitabine. It is applicable in situations where 5-FU/Capecitabine treatments are considered, especially colorectal, breast, pancreatic, and other GI cancers.
STAR Health Network DPYD Advantages
No additional tissue required
DPYD can be ordered as an add-on with the STAR Health Network xT Solid Tumor + Normal test, without additional tissue samples.
Expanded toxicity risk assessment
DPYD analysis covers five SNVs in DPYD genes, providing a more complete patient profile.
UGT1A1 Test
The STAR Health Network UGT1A1 test identifies patients at elevated risk for toxicity from treatment with irinotecan, sacituzumab govitecan, and/or belinostat.
The STAR Health Network UGT1A1 test identifies certain genetic polymorphisms in the UGT1A1 gene. These polymorphisms are associated with an elevated risk of developing toxicity to irinotecan, sacituzumab govitecan, and/or belinostat based on drug labeling. A patient who has one of the following genotypes will receive a positive test result: *28/*28, *6/*6, and *6/*28.
STAR Health Network UGT1A1 Advantages
No additional tissue required
UGT1A1 can be ordered as an add-on with the STAR Health Network xT Solid Tumor + Normal test, without additional tissue samples.
Expanded toxicity risk assessment
The STAR Health Network UGT1A1 test identifies 5 variants from 3 locations on the UGT1A1 gene, for a complete patient profile.